Bioprosthetic valve use has increased significantly. Considering their limited durability, there will remain an ongoing clinical need for repairing or replacing these prostheses in the future. The current standard of care for treating bioprosthetic valve degeneration involves redo open-heart surgery. However, repeat cardiac surgery may be associated with significant morbidity and mortality. With the rapid evolution of transcatheter heart valve therapies, the feasibility and safety of implanting a transcatheter heart valve within a failed tissue valve has been established. We review the historical perspective of transcatheter valve-in-valve therapy, as well as the main procedural challenges and clinical outcomes associated with this new less invasive treatment option. (J Am Coll Cardiol 2015;66:2019-37)
A pproximately 85,000 heart valve prostheses are implanted in the United States each year, and a total of 275,000 worldwide (1).
There are 2 main types of heart valve prostheses: 1) mechanical prosthetic valves, which require lifelong anticoagulation; and 2) tissue valves, which obviate the need for anticoagulation, but do not last as long as their mechanical counterparts. In the United States, the use of bioprosthetic aortic valve replacement increased from 26.7% in 1998 to 50.2% in 2005 (1,2). This major shift in the use of surgical bioprostheses, combined with their shorter durability and the increasing life expectancy of an aging population, is expected to translate into a major increase in the incidence of patients with surgical valve failure in the coming years.
The standard of care for degenerated bioprosthetic valves currently involves reoperative valve replacement. Over the last 2 decades, the mortality associated with redo aortic valve surgery has decreased significantly (3) (4) (5) . Nevertheless, depending on risk factors and patient status, the recognized mortality of bioprosthetic re-replacement for structural valve failure still ranges from 3% to 23% in most series (3, 6) . Transcatheter aortic valve replacement (TAVR) is now established as the preferred treatment option for inoperable patients and a valid alternative for highrisk individuals with severe symptomatic native aortic stenosis (8) . In recent years, following rapid evolution within the transcatheter valve field, the successful placement of new bioprosthetic valves via a transcatheter approach within degenerative aortic, mitral, tricuspid, and pulmonic surgical bioprostheses has been confirmed (9) (10) (11) (12) (13) . This study reviews the historical perspective, technical challenges, major risks, and outcomes associated with transcatheter valve-in-valve procedures in patients with failed left-sided (aortic and mitral) surgical bioprostheses.
SURGICAL BIOPROSTHETIC VALVES
Characteristics of the main surgical bioprostheses are summarized in Table 1 . Surgical heart valves are manufactured as either intra-annular or supraannular, and the portion visible on fluoroscopy can be either the stent frame or the sewing ring. The sewing ring is located at the bottom or 3 to 5 mm above the bottom of the stent frame in the supra-and intraannular valve designs, respectively (14) .
Stentless valves were developed to optimize the effective orifice area and thus facilitate left ventricular mass regression (15) . These valves do not have a base ring or a frame to support the leaflets, are sutured to the root in the actual position of the native valve, and can be of autograft, heterograft, or homograft origin (15, 16) .
More recently, sutureless valves that avoid the placement of sutures following annulus decalcification have been introduced, with the objective of reducing cross-clamp and cardiopulmonary bypass duration, and facilitating minimally invasive surgery and complex cardiac interventions (17) .
LABELING OF SURGICAL BIOPROSTHETIC VALVES. Surgical heart valve (SHV) sizing across manufacturers lacks standardization (18) . This may lead to confusion because the valve size labeling may correspond to internal or external diameters for stented valves, and to external diameter for stentless valves (7) . Consequently, 2 bioprostheses may have distinctive internal and external sewing ring diameters, despite having the same label size. For valve-in-valve therapy, the most relevant parameter relates to valve internal dimensions, which are often significantly smaller than the labeled valve size. Therefore, when envisioning a valve-in-valve procedure, it is imperative for the heart team to elicit the precise diameters of the failing bioprosthetic valve (usually available by reviewing published detailed tables providing valves dimensions (7, 19) or by consulting directly with the manufacturer). However, it is important to realize that, by convention, the stent internal diameter represents exclusively the internal dimension of a bare stent covered with fabric or pericardium, without accounting for the effect of artificial leaflets sutured within the stent (20) . Indeed, in a study conceived to assess the effect of tissue leaflets on stent internal diameter, the true internal valve diameter was smaller than the actual stent internal diameter in the majority of SHV designs (20) . Moreover, calcification or pannus can generate a discrepancy between the expected and the observed internal stent diameters. Recent studies have suggested that bioprosthetic valve calcification is an active rather than a passive process, and is modulated by numerous mechanisms, including lipid-mediated inflammation, immune response, and dysfunctional phosphocalcific metabolism (21) . Calcium deposits can be located on cuspal tissue (intrinsic calcification), but may also develop in thrombi or endocarditic vegetations (extrinsic calcification) (1). To attenuate calcification and further degeneration, glutaraldehyde valve leaflet pretreatment is widely used.
Another mechanism contributing to the limited lifespan of bioprosthetic valves is progressive collagen deterioration (1). Design-related tearing, rather than leaflet calcification, generally explains the deterioration of bovine pericardial valves (1) . The formation of tissue overgrowth (e.g., pannus), thrombus, or paravalvular leaks can usually explain bioprosthesis dysfunction not related to leaflet failure. Usually, valve stenosis is the consequence of calcification, pannus, or thrombus, whereas leaflet destruction or The mechanisms of aortic bioprosthetic dysfunction are equally distributed as predominantly stenotic, regurgitant, or mixed, with a higher rate of stenotic dysfunction among stented and smaller (#21 mm) valves, and a predominant regurgitant mechanism among stentless valves (11) . In mitral bioprostheses, regurgitation is the predominant mechanism of valve dysfunction (49%), followed by stenosis (21%) and combined mechanisms (30%) (22) .
The incidence of aortic and mitral bioprosthesis structural valve deterioration (SVD) requiring reintervention is 20% to 30% at 10 years and over 50% at 15 years (23,24) (Central Illustration). Because bioprosthetic valve calcification is hastened in younger individuals, the likelihood of primary tissue failure diminishes with age (1, 25, 26) (Figure 2) . Sénage et al. (27) showed that early valve failure is not infrequent and constitutes a life-threatening condition. A younger age at implantation, renal failure, hyperparathyroidism, higher post-operative gradients, prosthesis-patient mismatch (PPM), and mitral valve position are associated with a higher risk of tissue valve deterioration (21, 23, 24, 26) . One of the most likely hypotheses for the greater frequency of mitral bioprosthetic failure relative to aortic bioprosthetic failure may be partially related to the higher closeoff pressure in the mitral position (usually >100 mm Hg vs. <100 mm Hg in the aortic position). Also, the closure time is expected to be greater with a mitral prosthesis compared with an aortic prosthesis, possibly contributing to a higher degeneration rate (1) . Valve-in-Valve and Bioprosthetic Valve Dysfunction SHV ¼ surgical heart valve.
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Valve-in-Valve and Bioprosthetic Valve Dysfunction transvalvular) leaks, TEE should be routinely per- Incidence of bioprosthesis valve dysfunction and transcatheter aortic valve-in-valve and valve-in-ring as alternative treatments in those patients at high or prohibitive surgical risk.
Aspects of the main pre-procedural evaluation, risks, and results of transcatheter treatment of aortic and mitral bioprosthesis dysfunction are shown.
Valve-in-Valve and Bioprosthetic Valve Dysfunction (55) to achieve an optimal placement of THV devices inside a given surgical heart valve ( Table 1) . Paradis et al. There are some major differential aspects between conventional TAVR and valve-in-valve procedures. 
LATE OUTCOMES
Only a few valve-in-valve studies have reported 1-year survival rates (10,56,57,59-65). The mean mortality rate at 1 year has been 15.1% (ranging from 0% to 16.8%) ( Table 2) . 
MITRAL VALVE-IN-VALVE AND VALVE-IN-RING PROCEDURES
Perioperative mortality and morbidity exceeds 15% in patients >75 years of age after reoperation following a first mitral valve intervention (67) . Transcatheter valve-in-valve implantation, and, more recently, valve-in-ring procedures have emerged as less invasive alternatives to redo open heart surgery in selected patients deemed at high surgical risk. However, it should be stressed that these new procedures are performed with devices that were initially designed for the aortic or pulmonary valve. Therefore, they are still considered "off-label" and should be performed only as a last resort, when no other feasible options exist.
PRE-PROCEDURAL WORK-UP AND PROCEDURAL
ASPECTS. Similar to aortic valve-in-valve procedures, an accurate knowledge of the surgical mitral Paradis et al. 
MITRAL VALVE-IN-VALVE AND VALVE-IN-RING RESULTS
The reported results of the case series of mitral valve-in-valve and valve-in-ring published to date (43, 44, 68, (70) (71) (72) (73) (74) (75) (76) are shown in Table 5 Table 2 .
Valve-in-Valve and Bioprosthetic Valve Dysfunction
VALVE-IN-VALVE PROCEDURES: UNRESOLVED ISSUES AND FUTURE DIRECTIONS
The valve-in-valve proof-of-concept described by 
